Adjuvant Everolimus Falls Short in High-Risk Kidney Cancer
(MedPage Today) -- Adjuvant everolimus (Afinitor) failed to significantly improve recurrence-free survival (RFS) in patients with renal cell carcinoma (RCC) who were at high risk for recurrence after nephrectomy, according to results from a randomized...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Hematology | Kidney Cancer | Nephrectomy | Renal Cell Carcinoma | Urology & Nephrology